Acorda Therapeutics Inc ACORQ

Healthcare Biotechnology

Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. It also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.

OTCPK:ACORQ - Post by User

Acorda Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by Iseneschalon Oct 18, 2022 8:51am

97 Views

Post# 35030924

ACOR ... NR this a.m ... sh price down but lots of volume

I wonder if this is going to be another AGFY style ....go see my AGFY post ; )

Better be nimble......I tend to think that Mr. Maggot is going to leave Shareholders with "high priced paper" ....There is a meeting up-coming to vote on RS proposals.

JMHO

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario